Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

Tirzepatide 10mg

$115.00

Tirzepatide is a novel, once-weekly injectable medication that has revolutionized the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is a synthetic polypeptide and a "dual agonist" for two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual agonism allows tirzepatide to mimic the effects of both natural hormones, leading to enhanced glucose-dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and increased satiety, ultimately resulting in significant improvements in glycemic control and substantial weight loss. It is marketed under the brand names Mounjaro® for T2DM and Zepbound® for chronic weight management.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

Out of Stock

Data Sheet

Molecular Formula C225H348N48O68
CAS Number 2023788-19-2
Molar Mass 4813.527 g/mol
Amino Acid Sequence YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
PubChem CID 154666422
Primary Research Area Type 2 Diabetes Mellitus (T2DM)
Obesity
Weight Management
Glycemic Control
HbA1c Reduction
Cardiovascular Outcomes (CVOT)
Non-alcoholic Steatohepatitis (NASH) / Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Insulin Resistance
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism
Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonism
Appetite Suppression
Body Composition
Renal Outcomes
Purity >99%
Research Summary Description
Once-weekly Tirzepatide in patients with Type 2 diabetes Summary: This publication reports the results of SURPASS-1, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating tirzepatide as monotherapy in adults with type 2 diabetes who were treatment-naive. Participants received once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 40 weeks. All three doses of tirzepatide significantly reduced HbA1c and body weight from baseline compared to placebo. Notably, a high percentage of participants achieved HbA1c levels below 7% and even below 5.7% (non-diabetic range). Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common.

Citation:
Rosenstock, J., Wysham, P. C., Frías, J. P., Kaneko, S., Kawaguchi, Y., Manghi, F. P., ... & SURPASS-1 Investigators. (2021). Once-weekly tirzepatide in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Summary: SURPASS-4 was a Phase 3, open-label, randomized trial comparing tirzepatide (5 mg, 10 mg, or 15 mg once weekly) with insulin glargine once daily in patients with type 2 diabetes and increased cardiovascular risk whose glucose levels were inadequately controlled. The study's primary objective was to assess glycemic control, with a median follow-up of 85 weeks. Tirzepatide demonstrated superior HbA1c reductions and significantly greater weight loss compared to insulin glargine. Importantly, tirzepatide was associated with a lower risk of hypoglycemia compared to insulin glargine. The trial also showed a numerically lower rate of major adverse cardiovascular events (MACE) with tirzepatide, though it was not powered for MACE superiority.

Citation:
Del Prato, S., Kahn, S. E., Pavo, I., Lukashevich, V., Kozlovitski, D., Dahl, D., ... & SURPASS-4 Investigators. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10302), 1435–1446.
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (SURPASS-3 MRI) Summary: This post-hoc analysis of the SURPASS-3 MRI substudy investigated the impact of tirzepatide (pooled doses of 5 mg, 10 mg, and 15 mg) versus insulin degludec on thigh muscle volume, muscle volume Z-score (a measure invariant to weight), and muscle fat infiltration in patients with type 2 diabetes. Using MRI, the study found that while tirzepatide-induced weight reduction was associated with a decrease in absolute muscle volume, the changes in muscle volume were in line with what would be expected for the degree of weight loss observed. Crucially, tirzepatide significantly reduced muscle fat infiltration (myosteatosis) more favorably than insulin degludec, suggesting improved muscle quality.

Citation:
Sattar, N., Abadir, E., Ambery, P., Drouin, P., Frias, J. P., Lingvay, I., ... & SURPASS-3 MRI investigators. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (SURPASS-3 MRI). The Lancet Diabetes & Endocrinology, 13(2), 174-184.
Comparison of tirzepatide with dulaglutide on major cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: The SURPASS-CVOT trial. Summary: This highly anticipated Phase 3, event-driven, randomized, double-blind, active-controlled trial (SURPASS-CVOT) compared once-weekly tirzepatide (at maximum tolerated doses up to 15 mg) with once-weekly dulaglutide (1.5 mg) in over 13,000 adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary objective was to demonstrate non-inferiority of tirzepatide to dulaglutide for major adverse cardiovascular events (MACE-3: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). Topline results, recently announced, indicate that tirzepatide met the primary objective of non-inferiority, showing an 8% lower rate of MACE-3 events compared to dulaglutide (Hazard Ratio: 0.92; 95.3% CI: 0.83 to 1.01), which fell within the non-inferiority margin. Furthermore, while not primarily powered for superiority, tirzepatide also demonstrated numerically greater reductions in HbA1c and weight, and was associated with a 16% lower rate of all-cause death compared to dulaglutide.

Citation:
Eli Lilly and Company. (2025, July 31). Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated

Once-weekly Tirzepatide in patients with Type 2 diabetes

Summary: This publication reports the results of SURPASS-1, a Phase 3, randomized, double-blind, placebo-controlled trial evaluating tirzepatide as monotherapy in adults with type 2 diabetes who were treatment-naive. Participants received once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 40 weeks. All three doses of tirzepatide significantly reduced HbA1c and body weight from baseline compared to placebo. Notably, a high percentage of participants achieved HbA1c levels below 7% and even below 5.7% (non-diabetic range). Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common.

Citation:
Rosenstock, J., Wysham, P. C., Frías, J. P., Kaneko, S., Kawaguchi, Y., Manghi, F. P., ... & SURPASS-1 Investigators. (2021). Once-weekly tirzepatide in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515.

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Summary: SURPASS-4 was a Phase 3, open-label, randomized trial comparing tirzepatide (5 mg, 10 mg, or 15 mg once weekly) with insulin glargine once daily in patients with type 2 diabetes and increased cardiovascular risk whose glucose levels were inadequately controlled. The study's primary objective was to assess glycemic control, with a median follow-up of 85 weeks. Tirzepatide demonstrated superior HbA1c reductions and significantly greater weight loss compared to insulin glargine. Importantly, tirzepatide was associated with a lower risk of hypoglycemia compared to insulin glargine. The trial also showed a numerically lower rate of major adverse cardiovascular events (MACE) with tirzepatide, though it was not powered for MACE superiority.

Citation:
Del Prato, S., Kahn, S. E., Pavo, I., Lukashevich, V., Kozlovitski, D., Dahl, D., ... & SURPASS-4 Investigators. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10302), 1435–1446.

Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (SURPASS-3 MRI)

Summary: This post-hoc analysis of the SURPASS-3 MRI substudy investigated the impact of tirzepatide (pooled doses of 5 mg, 10 mg, and 15 mg) versus insulin degludec on thigh muscle volume, muscle volume Z-score (a measure invariant to weight), and muscle fat infiltration in patients with type 2 diabetes. Using MRI, the study found that while tirzepatide-induced weight reduction was associated with a decrease in absolute muscle volume, the changes in muscle volume were in line with what would be expected for the degree of weight loss observed. Crucially, tirzepatide significantly reduced muscle fat infiltration (myosteatosis) more favorably than insulin degludec, suggesting improved muscle quality.

Citation:
Sattar, N., Abadir, E., Ambery, P., Drouin, P., Frias, J. P., Lingvay, I., ... & SURPASS-3 MRI investigators. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial (SURPASS-3 MRI). The Lancet Diabetes & Endocrinology, 13(2), 174-184.

Comparison of tirzepatide with dulaglutide on major cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: The SURPASS-CVOT trial.

Summary: This highly anticipated Phase 3, event-driven, randomized, double-blind, active-controlled trial (SURPASS-CVOT) compared once-weekly tirzepatide (at maximum tolerated doses up to 15 mg) with once-weekly dulaglutide (1.5 mg) in over 13,000 adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary objective was to demonstrate non-inferiority of tirzepatide to dulaglutide for major adverse cardiovascular events (MACE-3: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). Topline results, recently announced, indicate that tirzepatide met the primary objective of non-inferiority, showing an 8% lower rate of MACE-3 events compared to dulaglutide (Hazard Ratio: 0.92; 95.3% CI: 0.83 to 1.01), which fell within the non-inferiority margin. Furthermore, while not primarily powered for superiority, tirzepatide also demonstrated numerically greater reductions in HbA1c and weight, and was associated with a 16% lower rate of all-cause death compared to dulaglutide.

Citation:
Eli Lilly and Company. (2025, July 31). Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping